What does this research mean for the field?

Analysis of the FDA Adverse Event Reporting System reveals that rosuvastatin exhibits stronger safety signals for muscular adverse events than pravastatin and atorvastatin, and that statins are generally associated with acute renal failure. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to examine the muscular and renal adverse events related to statins using FDA adverse event reports.

December 20, 2011PLoS ONEOpen Access

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System

View Full Paper

Ask AI

Bookmark

Why the study?

Do statins (pravastatin, simvastatin, atorvastatin, rosuvastatin) increase the risk of muscular and renal adverse events in the FDA Adverse Event Reporting System?

Population

1,644,220 adverse event reports submitted to the US Food and Drug Administration from 2004 to 2009

Comparison

Statins vs Other drugs in the adverse event reporting…

Design

Other

Authors

TSToshiyuki SakaedaKyoto Pharmaceutical University KKKaori KadoyamaOsaka University of Pharmaceutical Sciences YOYasushi OkunoKyoto University

Discussion

Member takes

Implication

Signals warrant ongoing vigilance for myopathy and renal events; leaves open comparative risks among statins for prospective confirmation.

Key Points

This research aims to examine the muscular and renal adverse events related to statins using FDA adverse event reports.
Analyzed 1,644,220 adverse event reports from 2004 to 2009 focusing on pravastatin, simvastatin, atorvastatin, and rosuvastatin.
Employed quantitative signal detection methods such as proportional reporting ratio and reporting odds ratio.
Focused on muscular events like myalgia and rhabdomyolysis, as well as renal events including acute renal failure.
Strong signals for myalgia, rhabdomyolysis, and increased creatine phosphokinase levels were found, particularly for rosuvastatin.
Marginal signals for acute renal failure were detected for atorvastatin, with no detection for non-acute renal failure or increased creatinine levels.
Results underscore the need for organized clinical studies on statin-associated adverse events.

Structured PICO

Do statins (pravastatin, simvastatin, atorvastatin, rosuvastatin) increase the risk of muscular and renal adverse events in the FDA Adverse Event Reporting System?

Population

1,644,220 adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) from 2004 to 2009

Intervention

Statins (pravastatin, simvastatin, atorvastatin, rosuvastatin)

Comparator

Other drugs in the adverse event reporting database (implicit in signal detection)

Outcome

Muscular adverse events (myalgia, rhabdomyolysis, increase in creatine phosphokinase level) and renal adverse events (acute renal failure, non-acute renal failure, increase in blood creatinine level)safety

Data mining of the FDA AERS database confirms safety signals for statin-associated muscular and renal adverse events, highlighting stronger muscular signals for rosuvastatin compared to pravastatin and atorvastatin.

Cite This Study

Sakaeda et al. (2011) studied this question.

synapsesocial.com/papers/6a1d237aba65f5ee325ddf4f https://doi.org/10.1371/journal.pone.0028124

Topics

Statin therapy

View Full Paper

Ask AI

Bookmark

Implication

Signals warrant ongoing vigilance for myopathy and renal events; leaves open comparative risks among statins for prospective confirmation.

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider